IDEXX Laboratories (NASDAQ:IDXX) CEO Jonathan Jay Mazelsky Sells 23,326 Shares

IDEXX Laboratories, Inc. (NASDAQ:IDXX) CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the sale, the chief executive officer owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. This represents a 21.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

IDEXX Laboratories Trading Down 3.0%

NASDAQ:IDXX traded down $20.03 during mid-day trading on Monday, reaching $636.70. The company’s stock had a trading volume of 522,026 shares, compared to its average volume of 514,219. The company’s fifty day simple moving average is $672.95 and its two-hundred day simple moving average is $669.12. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The stock has a market cap of $50.69 billion, a P/E ratio of 48.71, a P/E/G ratio of 3.99 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the firm earned $2.53 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Institutional Trading of IDEXX Laboratories

Several institutional investors have recently modified their holdings of IDXX. Reflection Asset Management bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $53,000. BDFS Capital LLC acquired a new stake in IDEXX Laboratories in the fourth quarter worth about $671,000. MidFirst Bank bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $2,960,000. Pacer Advisors Inc. lifted its stake in shares of IDEXX Laboratories by 10.0% in the 4th quarter. Pacer Advisors Inc. now owns 13,965 shares of the company’s stock valued at $9,448,000 after purchasing an additional 1,269 shares during the period. Finally, Titan Investment Management LLC bought a new position in IDEXX Laboratories during the fourth quarter worth about $1,675,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on IDXX shares. UBS Group decreased their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Finally, Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a report on Monday, November 3rd. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.